Intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno-occlusive disease model
Abstract Background Pulmonary veno-occlusive disease (PVOD) is a rare subtype of disease that causes pulmonary hypertension with vascular involvement of postcapillary structures of pulmonary vasculature. The disease has a poor prognosis with no effective therapy. The study aimed to determine whether...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-025-04400-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850105538688319488 |
|---|---|
| author | Junko Katagiri Jun Homma Ryo Takagi Hidekazu Sekine Takeshi Shinkawa Hiroshi Niinami Tatsuya Shimizu |
| author_facet | Junko Katagiri Jun Homma Ryo Takagi Hidekazu Sekine Takeshi Shinkawa Hiroshi Niinami Tatsuya Shimizu |
| author_sort | Junko Katagiri |
| collection | DOAJ |
| description | Abstract Background Pulmonary veno-occlusive disease (PVOD) is a rare subtype of disease that causes pulmonary hypertension with vascular involvement of postcapillary structures of pulmonary vasculature. The disease has a poor prognosis with no effective therapy. The study aimed to determine whether adipose-derived mesenchymal stem cells (ASCs) alleviate pulmonary hypertension and right ventricular hypertrophy in a rat model of PVOD. Methods Allogeneic ASCs were intravenously administered to a rat model of PVOD induced by mitomycin C. Then, muscularization in pulmonary microvessels, right ventricular systolic pressure (RVSP), and right ventricular hypertrophy were assessed using immunohistochemistry, right heart catheterization, heart weight, and hematoxylin–eosin (HE) staining. Body weight over time and survival rates were assessed. Results ASC transplantation substantially contributed to the reduction of pulmonary microvascular muscularization in the PVOD rat model but not to the decrease in RVSP. Furthermore, it led to the attenuation of right ventricular hypertrophy and a considerable decrease in wall thickness. However, repeated ASC administration increased the mortality rate in the PVOD rat models. Conclusions To the best of our knowledge, this is the first study to analyze the effects of ASC transplantation in a rat model of PVOD. While intravenous ASC transplantation exerts beneficial effects on the lungs and right ventricle, adverse events may occur depending on the administration method. Therefore, intravenous ASC transplantation should be performed with caution. |
| format | Article |
| id | doaj-art-23762bd0b87c40c3abfa1267657569a7 |
| institution | OA Journals |
| issn | 1757-6512 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj-art-23762bd0b87c40c3abfa1267657569a72025-08-20T02:39:03ZengBMCStem Cell Research & Therapy1757-65122025-05-0116111310.1186/s13287-025-04400-8Intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno-occlusive disease modelJunko Katagiri0Jun Homma1Ryo Takagi2Hidekazu Sekine3Takeshi Shinkawa4Hiroshi Niinami5Tatsuya Shimizu6Institute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, TWInsInstitute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, TWInsInstitute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, TWInsInstitute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, TWInsDepartment of Cardiovascular Surgery, School of Medicine, Tokyo Women’s Medical UniversityDepartment of Cardiovascular Surgery, School of Medicine, Tokyo Women’s Medical UniversityInstitute of Advanced Biomedical Engineering and Science, Tokyo Women’s Medical University, TWInsAbstract Background Pulmonary veno-occlusive disease (PVOD) is a rare subtype of disease that causes pulmonary hypertension with vascular involvement of postcapillary structures of pulmonary vasculature. The disease has a poor prognosis with no effective therapy. The study aimed to determine whether adipose-derived mesenchymal stem cells (ASCs) alleviate pulmonary hypertension and right ventricular hypertrophy in a rat model of PVOD. Methods Allogeneic ASCs were intravenously administered to a rat model of PVOD induced by mitomycin C. Then, muscularization in pulmonary microvessels, right ventricular systolic pressure (RVSP), and right ventricular hypertrophy were assessed using immunohistochemistry, right heart catheterization, heart weight, and hematoxylin–eosin (HE) staining. Body weight over time and survival rates were assessed. Results ASC transplantation substantially contributed to the reduction of pulmonary microvascular muscularization in the PVOD rat model but not to the decrease in RVSP. Furthermore, it led to the attenuation of right ventricular hypertrophy and a considerable decrease in wall thickness. However, repeated ASC administration increased the mortality rate in the PVOD rat models. Conclusions To the best of our knowledge, this is the first study to analyze the effects of ASC transplantation in a rat model of PVOD. While intravenous ASC transplantation exerts beneficial effects on the lungs and right ventricle, adverse events may occur depending on the administration method. Therefore, intravenous ASC transplantation should be performed with caution.https://doi.org/10.1186/s13287-025-04400-8Pulmonary veno-occlusive diseasePulmonary hypertensionMesenchymal stem cellsCell therapyVascular remodelingAdverse event |
| spellingShingle | Junko Katagiri Jun Homma Ryo Takagi Hidekazu Sekine Takeshi Shinkawa Hiroshi Niinami Tatsuya Shimizu Intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno-occlusive disease model Stem Cell Research & Therapy Pulmonary veno-occlusive disease Pulmonary hypertension Mesenchymal stem cells Cell therapy Vascular remodeling Adverse event |
| title | Intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno-occlusive disease model |
| title_full | Intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno-occlusive disease model |
| title_fullStr | Intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno-occlusive disease model |
| title_full_unstemmed | Intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno-occlusive disease model |
| title_short | Intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno-occlusive disease model |
| title_sort | intravenous mesenchymal stem cell transplantation mitigates pulmonary vascular remodeling but poses dose related risks in a pulmonary veno occlusive disease model |
| topic | Pulmonary veno-occlusive disease Pulmonary hypertension Mesenchymal stem cells Cell therapy Vascular remodeling Adverse event |
| url | https://doi.org/10.1186/s13287-025-04400-8 |
| work_keys_str_mv | AT junkokatagiri intravenousmesenchymalstemcelltransplantationmitigatespulmonaryvascularremodelingbutposesdoserelatedrisksinapulmonaryvenoocclusivediseasemodel AT junhomma intravenousmesenchymalstemcelltransplantationmitigatespulmonaryvascularremodelingbutposesdoserelatedrisksinapulmonaryvenoocclusivediseasemodel AT ryotakagi intravenousmesenchymalstemcelltransplantationmitigatespulmonaryvascularremodelingbutposesdoserelatedrisksinapulmonaryvenoocclusivediseasemodel AT hidekazusekine intravenousmesenchymalstemcelltransplantationmitigatespulmonaryvascularremodelingbutposesdoserelatedrisksinapulmonaryvenoocclusivediseasemodel AT takeshishinkawa intravenousmesenchymalstemcelltransplantationmitigatespulmonaryvascularremodelingbutposesdoserelatedrisksinapulmonaryvenoocclusivediseasemodel AT hiroshiniinami intravenousmesenchymalstemcelltransplantationmitigatespulmonaryvascularremodelingbutposesdoserelatedrisksinapulmonaryvenoocclusivediseasemodel AT tatsuyashimizu intravenousmesenchymalstemcelltransplantationmitigatespulmonaryvascularremodelingbutposesdoserelatedrisksinapulmonaryvenoocclusivediseasemodel |